TACE for treatment-naive HCC has different treatment effects depending on central or peripheral tumor-location

医学 外围设备 肝细胞癌 内科学 经导管动脉化疗栓塞 胃肠病学 倾向得分匹配 肿瘤科 放射科
作者
Kazuo Asano,Ken Kageyama,A. Yamamoto,Atsushi Jogo,Sawako Uchida‐Kobayashi,Etsuji Sohgawa,Kazuki Murai,Norifumi Kawada,Yukio Miki
出处
期刊:Liver cancer [Karger Publishers]
卷期号:12 (6): 576-589
标识
DOI:10.1159/000530441
摘要

The purpose of this study was to evaluate the treatment efficacy of transcatheter arterial chemoembolization (TACE) for treatment-naive hepatocellular carcinoma (HCC) according to tumor location and burden.Between 2010 and 2019, consecutive patients who underwent TACE as the first treatment were enrolled. Tumors were classified into two categories based on their location, as central or peripheral tumors. Tumors in the central zone, which is within 1 cm of the main trunk or the first branch of the portal vein, were classified as central tumors, while those located in the peripheral zone were classified as peripheral tumors. Patients were grouped according to the HCC location and up-to-7 criteria. Patients with central tumors were classified into the central arm and those with only peripheral tumors were classified into the peripheral arm. Patients within and beyond the up-to-7 criteria were classified into the up-to-7 in and up-to-7 out-groups, respectively. Local recurrence-free survival (LRFS) and progression-free survival (PFS) were compared per nodule (central tumor vs. peripheral tumor) and per patient (central arm vs. peripheral arm), respectively. The prognostic factors of LRFS and PFS were analyzed by univariate and multivariate analyses.A total of 174 treatment-naive patients with 352 HCCs were retrospectively enrolled. Ninety-six patients and 130 lesions were selected by propensity score matching. Median LRFS was longer for peripheral tumors than central tumors (not reached vs. 3.3 months, p < 0.001). Median PFS was 17.1 months (8.3-24.9) in the peripheral arm and up-to-7 in, 7.0 months (3.3-12.7) in the peripheral arm and up-to-7 out, 8.4 months (4.0-12.6) in the central arm and up-to-7 in, and 3.0 months (1.2-4.9) in the central arm and up-to-7 out-groups. The peripheral arm and up-to-7 in-groups had significantly longer PFS than the other three groups (p = 0.013, p = 0.015, p < 0.001, respectively). Multivariate analysis confirmed that the central zone and central arm were associated with high adjusted hazard ratios for tumor recurrence or death (2.87, p < 0.001; 2.89, p < 0.001, respectively).Treatment-naive HCCs in the peripheral zone had a longer LRFS and PFS following TACE compared to those in the central zone.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
shouz完成签到,获得积分10
1秒前
Waiting完成签到 ,获得积分10
2秒前
kkdsseed的应助被hqc8866采纳,获得10
2秒前
toppkj发布了新的文献求助10
2秒前
123wzl123完成签到,获得积分10
2秒前
xiaoxiao完成签到 ,获得积分10
3秒前
芷诺完成签到 ,获得积分10
3秒前
yanglala完成签到 ,获得积分10
4秒前
英勇含烟完成签到,获得积分10
4秒前
快乐谷蓝完成签到,获得积分10
4秒前
qss完成签到,获得积分10
5秒前
云朵杰瑞完成签到,获得积分10
5秒前
许自通完成签到,获得积分10
5秒前
云中月完成签到,获得积分10
6秒前
妩媚的问玉完成签到,获得积分10
6秒前
无敌干扰素完成签到,获得积分10
8秒前
TonyXWZhang完成签到,获得积分10
9秒前
在九月完成签到 ,获得积分10
9秒前
fishswim1完成签到,获得积分10
11秒前
刘华珍完成签到,获得积分10
13秒前
13秒前
段辉完成签到,获得积分10
14秒前
Lucas的应助被toppkj采纳,获得10
15秒前
lizhehao完成签到,获得积分10
15秒前
香蕉觅云的应助被紫熊采纳,获得10
15秒前
TY完成签到 ,获得积分10
16秒前
szjqq完成签到,获得积分10
16秒前
rzxhygr完成签到,获得积分10
17秒前
乔凌云完成签到 ,获得积分10
18秒前
天天快乐的应助被学术雷锋采纳,获得10
19秒前
陨落的繁星完成签到,获得积分10
19秒前
务实青筠完成签到 ,获得积分10
20秒前
nusiew完成签到,获得积分10
20秒前
勤奋的毛豆完成签到,获得积分10
20秒前
爱沉淀的太阳花完成签到,获得积分10
21秒前
热心的梦柏完成签到 ,获得积分10
22秒前
织梦完成签到 ,获得积分10
22秒前
tszjw168发布了新的文献求助10
23秒前
szj完成签到,获得积分10
23秒前
星星完成签到 ,获得积分10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159131
求助须知:如何正确求助?哪些是违规求助? 9554607
关于积分的说明 21719706
捐赠科研通 7748769
什么是DOI,文献DOI怎么找? 3427149
关于科研通互助平台的介绍 2552079
邀请新用户注册赠送积分活动 2471428